Navigation Links
Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
Date:3/18/2008

- Study to Assess MEDI-528 in Stable Asthma and Exercise-Induced

Bronchoconstriction -

PLYMOUTH MEETING, Pa., March 18 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported that development partner, MedImmune, has initiated its fourth phase 2a clinical trial of MEDI-528, an anti-IL-9 monoclonal antibody (MAb) targeting interleukin-9 (IL-9), in patients with asthma. This clinical trial is designed to assess the potential of MEDI-528 in patients with stable asthma and exercise-induced bronchoconstriction. Genaera and MedImmune entered into a research collaboration and licensing agreement for this program in 2001.

MedImmune is currently evaluating MEDI-528 in patients with asthma in a series of phase 2 clinical trials. The goal of the current phase 2a trial is to assess the safety and tolerability of multiple fixed escalating doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction. The study will also assess the effect of MEDI-528 on exercise challenge testing, as well as the pharmacokinetics and immunogenicity of the investigational treatment. Enrollment of this randomized, double-blind, placebo-controlled trial will take place at multiple sites throughout the U.S. and Canada.

Genaera also noted that MedImmune announced preliminary safety results from an ongoing phase 2 clinical trial of MEDI-528, supporting continued development of the antibody in the mild-to-moderate asthmatic subjects in that trial. Two phase 1 single-dose, dose-escalation studies were previously conducted to evaluate the safety, tolerability and pharmacokinetics of the anti-IL-9 MAb in healthy volunteers. In addition, preclinical data suggest that blocking I
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional ... Toronto -based 3D visualization leader ... Congress of Neurological Surgeons Annual Meeting that they ... for brain surgery. The collaboration is the first ... combination to improve patient outcomes. NICO,s BrainPath® interventional ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics announced ... the ability to collect human data at 30X depth, sufficient ... chip.  This new capability was established and demonstrated for the ... Irys TM System and will be rolled out ... BioNano will be showcasing this advancement at the American ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs ... facility in Albany, NY for ... The company meets and/or exceeds the FDA standards for ... 21 CFR Part 211. The 10,000 ... highest levels of quality assurance and quality control. The ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... 20, 2014 Succeed is proud to announce ... who participated in the Every Body Walk! campaign ... awareness project that encourages workers to be more active outside ... Program, which concluded at the end of September, was a ... and metro areas. Participating companies gave their staff pedometers ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Do you ever feel difficulty in ... wonderful app Metassessor for teachers, specialists and parents. SIMpalm, ... its client “Intervention Development LLC” to launch Metassessor App ... for iOS 4.3 or later and is Compatible with ... for iPhone 5. It is now available on Apple ...
(Date:10/19/2014)... Dr. Babatunde Osotimehin, Executive Director of ... a ceasefire agreement that is expected to lead to ... were kidnapped from the north-eastern Nigerian town of Chibok—the ... enough, and it is high time they are returned ... , "We owe it to these girls to positively ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Biogen Idec announced the national launch of the new AVONEX(R) ... people //with multiple sclerosis (MS) as they begin and continue ... of MS worldwide. ,"As a person living with ... nurses play an important role in working closely with patients ...
... An anti-reflux valve developed to help esophageal cancer patients also ... according to a research//. The study, using the anti-reflux ... bile duct, appears in the May issue of Gastrointestinal Endoscopy ... Anti-Reflux Valve,” named after its inventor, was cleared for use ...
... 65 who lacked health insurance for a year has risen from ... of uninsured residents ranged from a low of 13.4 percent in ... ,Lack of health insurance is a particularly acute problem ... highest proportion of uninsured lie east of Interstate 95. ...
... to take its toll and the number of injured soldiers ... have// lost their limbs. ,The Johns Hopkins University ... team has developed a breakthrough prosthetic arm under the Defense ... ,That program is an initiative to produce by 2009 ...
... How your food is cooked may be as important to ... about a new class of toxins that might soon become// ... disorders as trans fats. ,This class of ... the body through the consumption of grilled, fried, or broiled ...
... representatives have looked at the growing need to understand ... staff and managers across the health service. ... and perceptions of digital libraries (sources of non-personal health ... the introduction of new technologies in particular healthcare contexts ...
Cached Medicine News:Health News:Multiple Sclerosis Patients to Benefit With AVONEX(R) Nurse Services Program 2Health News:Cancer Patient’s Life Improved With Anti-reflux Valv 2Health News:Cancer Patient’s Life Improved With Anti-reflux Valv 3Health News:Number of Uninsured in North Carolina on the Rise 2Health News:A Realistic Arm on the Anvil for Injured Soldiers 2Health News:Food Preparation may Play a Bigger Role in Chronic Disease 2Health News:Food Preparation may Play a Bigger Role in Chronic Disease 3Health News:Food Preparation may Play a Bigger Role in Chronic Disease 4
... assays for the detection and ... extractable nuclear antigens (ENA)RNP, Sm ... Sm aid in the diagnosis ... ,RNP antibodies aid in the ...
... ENA Multiparameter Kit is designed ... six of the most common ... unique quality control system. The ... well in each strip gives ...
... The assay uses highly pure, functional human ... immune complexes (CIC). In the first stage, CIC ... the controls and standards are dispensed into the ... is removed in a washing step and a ...
The K-ASSAY® D-Dimer Control set is intended to be used a consistent test sample of known concentration for monitoring the performance of D-Dimer immunoturbidimetric assays....
Medicine Products: